by Dr. Yann Neuzillet, Priscilla Leon, Marie-Magdelaine Coudé
As part of the TVNIM-AFU registry, Cerba Laboratory has partnered with the French Association of Urology (AFU) and Oncodiag to develop a CE-marked molecular test based on the analysis of a urine sample, designed for individualized monitoring of patients treated for Non-Muscle Invasive Bladder Cancer (NMIBC) with low, intermediate, and high risk of recurrence.
The purpose of this registry is to demonstrate that this new test could help reduce the frequency of cystoscopies.
